American Capital Management significantly increased its investment in Novanta Inc. during the fourth quarter of 2025, acquiring 163,005 additional shares at an approximate cost of $18.56 million, according to a recent SEC filing. The institutional investor's total position in the precision optics and photonics company now stands at 381,866 shares, valued at approximately $45.44 million, underscoring continued confidence in the company's long-term prospects.
The increased stake comes amid a period of modest financial performance for Novanta, which reported revenue growth of just 1.4% in recent periods. The company's valuation presents a notable premium to broader market indices, with a price-to-earnings ratio of approximately 99x, reflecting investor expectations for future earnings acceleration and margin expansion.
Market conditions for Novanta's core business segments show signs of stabilization and recovery. The company's exposure to medical device original equipment manufacturers and industrial OEM sectors—both of which have demonstrated cyclical recovery patterns—may have influenced American Capital Management's decision to deepen its investment position during this period.